Literature DB >> 18990164

Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density.

Christian Bolenz1, Shahrokh F Shariat, Mario I Fernández, Vitaly Margulis, Yair Lotan, Pierre Karakiewicz, Mesut Remzi, Eiji Kikuchi, Richard Zigeuner, Alon Weizer, Francesco Montorsi, Karim Bensalah, Christopher G Wood, Marco Roscigno, Cord Langner, Theresa M Koppie, Jay D Raman, Shuji Mikami, Maurice Stephan Michel, Philipp Ströbel.   

Abstract

OBJECTIVE: To determine the risk factors associated with clinical outcome in patients with lymph node (LN)-positive urothelial carcinoma of the upper urinary tract (UTUC) treated with radical nephroureterectomy (RNU) and lymphadenectomy, focusing on the concept of LN density (LND). PATIENTS AND METHODS: Patients undergoing RNU with regional lymphadenectomy were identified through multi-institutional databases. All pathology slides were re-evaluated by genitourinary pathologists unaware of the clinical data. The exposure variable used was LND (continuously coded and that of all possible thresholds) with recurrence-free and disease-specific survival (DSS) serving as the outcome measures.
RESULTS: Of 432 patients undergoing RNU with lymphadenectomy, 135 (31%) had LN metastases. Within a median follow-up of 4.1 years, 90 of the 135 patients with LN metastases (68%) had disease recurrence and 76 (58%) died from UTUC. The mean (sem) 5-year recurrence-free and DSS probabilities were 27 (4)% and 33 (5)%, respectively. The median (range) LND was 50 (3-100)%. The most informative threshold for LND in relation to outcome was 30%. In multivariable analyses that adjusted for the effects of tumour stage and grade, patients with a LND of > or =30% were at greater risk of both cancer recurrence, with 5-year rates of 25 (5)% vs 38 (8)% (hazard ratio 1.8, P = 0.021) and mortality, with 5-year rates of 30 (6)% vs 48 (9)% (1.7, P = 0.032) compared to those with a LND of <30%. Our results are primarily limited by a lack of standardization in the lymphadenectomy template.
CONCLUSION: We evaluated the concept of LND for the first time in UTUC. LND provides additional prognostic information in patients with node-positive disease after RNU. The use of LND in clinical trials might provide an additional insight into the value of LN dissection in patients undergoing RNU.

Entities:  

Mesh:

Year:  2008        PMID: 18990164     DOI: 10.1111/j.1464-410X.2008.07988.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  29 in total

1.  [Urothelial carcinoma of the upper urinary tract: clinical and pathological criteria and their predictive implications after radical nephroureterectomy].

Authors:  Christian Seitz; Paul Schramek
Journal:  Wien Med Wochenschr       Date:  2011-08

Review 2.  [Upper tract urothelial carcinoma. An update on clinical and pathological prognostic factors].

Authors:  M Rink; M Adam; J Hansen; F K Chun; S A Ahyai; M Remzi; T Schlomm; O Engel; R Heuer; C Eichelberg; M Fisch; R Dahlem; S F Shariat
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

3.  Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract.

Authors:  Piotr Zareba; Barak Rosenzweig; Andrew G Winer; Jonathan A Coleman
Journal:  Cancer       Date:  2017-02-02       Impact factor: 6.860

4.  Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years?

Authors:  Mesut Remzi; Shahrokh Shariat; Wilhelm Huebner; Harun Fajkovic; Christian Seitz
Journal:  Ther Adv Urol       Date:  2011-04

Review 5.  Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review.

Authors:  Aurélie Mbeutcha; Morgan Rouprêt; Ashish M Kamat; Pierre I Karakiewicz; Nathan Lawrentschuk; Giacomo Novara; Jay D Raman; Christian Seitz; Evanguelos Xylinas; Shahrokh F Shariat
Journal:  World J Urol       Date:  2016-04-21       Impact factor: 4.226

Review 6.  Prognostic factors for upper urinary tract urothelial carcinoma.

Authors:  Thomas F Chromecki; Karim Bensalah; Mesut Remzi; Grégory Verhoest; Eugene K Cha; Douglas S Scherr; Giacomo Novara; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  Nat Rev Urol       Date:  2011-07-05       Impact factor: 14.432

7.  The impact of lymph node status and features on oncological outcomes in urothelial carcinoma of the upper urinary tract (UTUC) treated by nephroureterectomy.

Authors:  Adil Ouzzane; Pierre Colin; Tarek P Ghoneim; Marc Zerbib; Alexandre De La Taille; François Audenet; Fabien Saint; Nicolas Hoarau; Emilie Adam; Marie Dominique Azemar; Henri Bensadoun; Luc Cormier; Olivier Cussenot; Alain Houlgatte; Gilles Karsenty; Charlotte Maurin; François Xavier Nouhaud; Véronique Phe; Thomas Polguer; Mathieu Roumiguié; Alain Ruffion; Morgan Rouprêt
Journal:  World J Urol       Date:  2012-12-11       Impact factor: 4.226

8.  Current Status of Lymphadenectomy During Radical Nephroureterectomy for Upper Tract Urothelial Cancer-Yes, No or Maybe?

Authors:  Ashwin Sunil Tamhankar; Saurabh Ramesh Patil; Puneet Ahluwalia; Gagan Gautam
Journal:  Indian J Surg Oncol       Date:  2018-08-13

9.  The method of bladder cuff excision during laparoscopic radical nephroureterectomy does not affect oncologic outcomes in upper tract urothelial carcinoma.

Authors:  Christopher B Allard; Abdulaziz Alamri; Shawn Dason; Farough Farrokhyar; Edward D Matsumoto; Anil Kapoor
Journal:  World J Urol       Date:  2012-07-29       Impact factor: 4.226

10.  Human epidermal growth factor receptor 2 expression in urothelial carcinoma of the renal pelvis: correlation with clinicopathologic parameters.

Authors:  Laleh Ehsani; Adeboye O Osunkoya
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.